Portal de Periódicos da CAPES

What makes a blood cell based miRNA expression pattern disease specific? - A miRNome analysis of blood cell subsets in lung cancer patients and healthy controls

2014; Impact Journals LLC; Volume: 5; Issue: 19 Linguagem: Inglês

10.18632/oncotarget.2419

1949-2553

Petra Leidinger, Christina Backes, Indra Navina Dahmke, Valentina Galata, Hanno Huwer, Ingo Stehle, Robert Bals, Andreas Keller, Eckart Meese,

Circular RNAs in diseases

// Petra Leidinger 1, * , Christina Backes 2, * , Indra N. Dahmke 3 , Valentina Galata 2 , Hanno Huwer 4 , Ingo Stehle 5 , Robert Bals 5 , Andreas Keller 2 , Eckart Meese 1 1 Institute of Human Genetics, Medical School, Saarland University, Building 60, 66421 Homburg/Saar, Germany 2 Department of Clinical Bioinformatics, Saarland University, Building E2.1, 66123 Saarbrücken, Germany 3 Institute for Clinical and Experimental Surgery, Saarland University, Building 65, 66421 Homburg/Saar, Germany 4 Department of Thoracic Surgery, Voelklingen Heart Center, 66333 Voelklingen Germany 5 Department of Pneumology, Medical School, Saarland University, Building 91, 66421 Homburg/Saar, Germany * Equally contributed as first authors Correspondence to: Dr. Petra Leidinger, e-mail: p.leidinger@mx.uni-saarland.de Key words: microRNA, leukocytes, lung cancer, microarray, cell separation Received: July 16, 2014 Accepted: August 28, 2014 Published: September 19, 2014 ABSTRACT There is evidence of blood-borne miRNA signatures for various human diseases. To dissect the origin of disease-specific miRNA expression in human blood, we separately analyzed the miRNome of different immune cell subtypes, each in lung cancer patients and healthy individuals. Each immune cell type revealed a specific miRNA expression pattern also dependinging on the cell origin, line of defense, and function. The overall expression pattern of each leukocyte subtype showed great similarities between patients and controls. However, for each cell subtype we identified miRNAs that were deregulated in lung cancer patients including hsa-miR-21, a well-known oncomiR associated with poor lung cancer prognosis that was up-regulated in all leukocyte subtype comparisons of cancer versus controls. While the miRNome of cells of the adaptive immune system allowed only a weak separation between patients and controls, cells of the innate immune system allowed perfect or nearly perfect classification. Leukocytes of lung cancer patients show a cancer-specific miRNA expression profile. Our data also show that cancer specific miRNA expression pattern of whole blood samples are not determined by a single cell type. The data indicate that additional blood components, like erythrocytes, platelets, or exosomes might contribute to the disease specificity of a miRNA signature.